nodes	percent_of_prediction	percent_of_DWPC	metapath
Progesterone—ESR1—urinary bladder cancer	0.301	1	CbGaD
Progesterone—ABCC1—Epirubicin—urinary bladder cancer	0.0366	0.0995	CbGbCtD
Progesterone—ABCB1—Mitomycin—urinary bladder cancer	0.0335	0.091	CbGbCtD
Progesterone—ABCC1—Etoposide—urinary bladder cancer	0.0285	0.0775	CbGbCtD
Progesterone—CYP1B1—Doxorubicin—urinary bladder cancer	0.0274	0.0744	CbGbCtD
Progesterone—ABCB11—Doxorubicin—urinary bladder cancer	0.0274	0.0744	CbGbCtD
Progesterone—SLC22A2—Cisplatin—urinary bladder cancer	0.0263	0.0715	CbGbCtD
Progesterone—CYP2A6—Fluorouracil—urinary bladder cancer	0.0247	0.0671	CbGbCtD
Progesterone—ABCC1—Doxorubicin—urinary bladder cancer	0.0194	0.0529	CbGbCtD
Progesterone—ABCC1—Methotrexate—urinary bladder cancer	0.0188	0.0512	CbGbCtD
Progesterone—CYP3A4—Thiotepa—urinary bladder cancer	0.0152	0.0413	CbGbCtD
Progesterone—CYP2C8—Fluorouracil—urinary bladder cancer	0.0122	0.0331	CbGbCtD
Progesterone—CYP3A5—Etoposide—urinary bladder cancer	0.0106	0.0287	CbGbCtD
Progesterone—CYP2C8—Etoposide—urinary bladder cancer	0.0102	0.0276	CbGbCtD
Progesterone—ABCB1—Gemcitabine—urinary bladder cancer	0.00963	0.0262	CbGbCtD
Progesterone—CYP1A2—Fluorouracil—urinary bladder cancer	0.00942	0.0256	CbGbCtD
Progesterone—CYP2C9—Fluorouracil—urinary bladder cancer	0.00849	0.0231	CbGbCtD
Progesterone—CYP1A2—Etoposide—urinary bladder cancer	0.00786	0.0214	CbGbCtD
Progesterone—CYP2C9—Cisplatin—urinary bladder cancer	0.00721	0.0196	CbGbCtD
Progesterone—AR—scrotum—urinary bladder cancer	0.00704	0.0924	CbGeAlD
Progesterone—ABCB1—Cisplatin—urinary bladder cancer	0.007	0.019	CbGbCtD
Progesterone—ABCB1—Etoposide—urinary bladder cancer	0.00687	0.0187	CbGbCtD
Progesterone—ABCB1—Doxorubicin—urinary bladder cancer	0.00469	0.0128	CbGbCtD
Progesterone—ABCB1—Methotrexate—urinary bladder cancer	0.00454	0.0124	CbGbCtD
Progesterone—CYP2D6—Doxorubicin—urinary bladder cancer	0.00442	0.012	CbGbCtD
Progesterone—CYP3A4—Etoposide—urinary bladder cancer	0.00412	0.0112	CbGbCtD
Progesterone—AR—penis—urinary bladder cancer	0.00318	0.0417	CbGeAlD
Progesterone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00281	0.00764	CbGbCtD
Progesterone—CYP2C19—urine—urinary bladder cancer	0.00196	0.0257	CbGeAlD
Progesterone—SLC10A1—prostate gland—urinary bladder cancer	0.00163	0.0214	CbGeAlD
Progesterone—CYP1A2—urine—urinary bladder cancer	0.0016	0.021	CbGeAlD
Progesterone—NR3C1—urine—urinary bladder cancer	0.00153	0.0201	CbGeAlD
Progesterone—CYP2C9—urine—urinary bladder cancer	0.00152	0.0199	CbGeAlD
Progesterone—OPRK1—prostate gland—urinary bladder cancer	0.00143	0.0188	CbGeAlD
Progesterone—SLC10A1—seminal vesicle—urinary bladder cancer	0.00138	0.0181	CbGeAlD
Progesterone—CYP3A4—urine—urinary bladder cancer	0.00116	0.0152	CbGeAlD
Progesterone—CYP2D6—urine—urinary bladder cancer	0.00114	0.0149	CbGeAlD
Progesterone—SLC10A1—renal system—urinary bladder cancer	0.00111	0.0146	CbGeAlD
Progesterone—CYP2A6—prostate gland—urinary bladder cancer	0.00109	0.0143	CbGeAlD
Progesterone—SHBG—prostate gland—urinary bladder cancer	0.00106	0.0139	CbGeAlD
Progesterone—NR3C2—prostate gland—urinary bladder cancer	0.00102	0.0134	CbGeAlD
Progesterone—CYP17A1—renal system—urinary bladder cancer	0.000967	0.0127	CbGeAlD
Progesterone—PGR—prostate gland—urinary bladder cancer	0.000953	0.0125	CbGeAlD
Progesterone—CYP2A6—seminal vesicle—urinary bladder cancer	0.000925	0.0121	CbGeAlD
Progesterone—SLC10A1—female reproductive system—urinary bladder cancer	0.000889	0.0117	CbGeAlD
Progesterone—SLC22A2—renal system—urinary bladder cancer	0.00088	0.0115	CbGeAlD
Progesterone—SLC22A3—prostate gland—urinary bladder cancer	0.000872	0.0114	CbGeAlD
Progesterone—NR3C2—seminal vesicle—urinary bladder cancer	0.000867	0.0114	CbGeAlD
Progesterone—SIGMAR1—prostate gland—urinary bladder cancer	0.000843	0.0111	CbGeAlD
Progesterone—Trilostane—ESR2—urinary bladder cancer	0.00083	0.23	CrCbGaD
Progesterone—CYP1B1—prostate gland—urinary bladder cancer	0.000801	0.0105	CbGeAlD
Progesterone—OPRK1—female reproductive system—urinary bladder cancer	0.000783	0.0103	CbGeAlD
Progesterone—CYP17A1—female reproductive system—urinary bladder cancer	0.000774	0.0102	CbGeAlD
Progesterone—AR—prostate gland—urinary bladder cancer	0.000759	0.00996	CbGeAlD
Progesterone—ESR1—prostate gland—urinary bladder cancer	0.000745	0.00977	CbGeAlD
Progesterone—SLC22A3—seminal vesicle—urinary bladder cancer	0.000737	0.00967	CbGeAlD
Progesterone—NR3C2—smooth muscle tissue—urinary bladder cancer	0.000726	0.00952	CbGeAlD
Progesterone—ABCC1—prostate gland—urinary bladder cancer	0.000721	0.00946	CbGeAlD
Progesterone—SIGMAR1—seminal vesicle—urinary bladder cancer	0.000713	0.00935	CbGeAlD
Progesterone—PGR—epithelium—urinary bladder cancer	0.0007	0.00918	CbGeAlD
Progesterone—NR3C2—renal system—urinary bladder cancer	0.000698	0.00916	CbGeAlD
Progesterone—NR3C2—urethra—urinary bladder cancer	0.000686	0.009	CbGeAlD
Progesterone—PGR—smooth muscle tissue—urinary bladder cancer	0.000674	0.00885	CbGeAlD
Progesterone—AR—seminal vesicle—urinary bladder cancer	0.000642	0.00842	CbGeAlD
Progesterone—SLC22A1—renal system—urinary bladder cancer	0.000622	0.00816	CbGeAlD
Progesterone—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.000617	0.0081	CbGeAlD
Progesterone—ABCC1—seminal vesicle—urinary bladder cancer	0.00061	0.008	CbGeAlD
Progesterone—SIGMAR1—smooth muscle tissue—urinary bladder cancer	0.000597	0.00783	CbGeAlD
Progesterone—SLC22A3—renal system—urinary bladder cancer	0.000594	0.0078	CbGeAlD
Progesterone—SLC22A3—urethra—urinary bladder cancer	0.000584	0.00766	CbGeAlD
Progesterone—SHBG—female reproductive system—urinary bladder cancer	0.000577	0.00757	CbGeAlD
Progesterone—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.000567	0.00744	CbGeAlD
Progesterone—SIGMAR1—urethra—urinary bladder cancer	0.000564	0.0074	CbGeAlD
Progesterone—NR3C2—female reproductive system—urinary bladder cancer	0.000559	0.00734	CbGeAlD
Progesterone—AR—epithelium—urinary bladder cancer	0.000558	0.00732	CbGeAlD
Progesterone—Ethynodiol—ESR1—urinary bladder cancer	0.000555	0.154	CrCbGaD
Progesterone—CYP3A5—prostate gland—urinary bladder cancer	0.000554	0.00727	CbGeAlD
Progesterone—NR3C1—prostate gland—urinary bladder cancer	0.00055	0.00721	CbGeAlD
Progesterone—ESR1—epithelium—urinary bladder cancer	0.000547	0.00718	CbGeAlD
Progesterone—CYP1B1—renal system—urinary bladder cancer	0.000546	0.00717	CbGeAlD
Progesterone—CYP2A6—vagina—urinary bladder cancer	0.00054	0.00708	CbGeAlD
Progesterone—AR—smooth muscle tissue—urinary bladder cancer	0.000537	0.00705	CbGeAlD
Progesterone—ESR1—smooth muscle tissue—urinary bladder cancer	0.000527	0.00692	CbGeAlD
Progesterone—SHBG—vagina—urinary bladder cancer	0.000522	0.00685	CbGeAlD
Progesterone—PGR—female reproductive system—urinary bladder cancer	0.00052	0.00682	CbGeAlD
Progesterone—AR—renal system—urinary bladder cancer	0.000517	0.00679	CbGeAlD
Progesterone—Trilostane—ESR1—urinary bladder cancer	0.000511	0.142	CrCbGaD
Progesterone—AR—urethra—urinary bladder cancer	0.000508	0.00667	CbGeAlD
Progesterone—ESR1—renal system—urinary bladder cancer	0.000508	0.00666	CbGeAlD
Progesterone—NR3C2—vagina—urinary bladder cancer	0.000506	0.00664	CbGeAlD
Progesterone—ABCC1—urethra—urinary bladder cancer	0.000483	0.00633	CbGeAlD
Progesterone—SLC22A3—female reproductive system—urinary bladder cancer	0.000476	0.00624	CbGeAlD
Progesterone—Norgestimate—ESR1—urinary bladder cancer	0.000472	0.131	CrCbGaD
Progesterone—PGR—vagina—urinary bladder cancer	0.00047	0.00617	CbGeAlD
Progesterone—NR3C1—seminal vesicle—urinary bladder cancer	0.000465	0.0061	CbGeAlD
Progesterone—CYP17A1—lymph node—urinary bladder cancer	0.000453	0.00594	CbGeAlD
Progesterone—SLC22A1—vagina—urinary bladder cancer	0.00045	0.00591	CbGeAlD
Progesterone—CYP1B1—female reproductive system—urinary bladder cancer	0.000437	0.00574	CbGeAlD
Progesterone—SLC22A3—vagina—urinary bladder cancer	0.00043	0.00565	CbGeAlD
Progesterone—CYP2C8—renal system—urinary bladder cancer	0.000418	0.00549	CbGeAlD
Progesterone—CYP1A1—epithelium—urinary bladder cancer	0.000416	0.00546	CbGeAlD
Progesterone—SIGMAR1—vagina—urinary bladder cancer	0.000416	0.00546	CbGeAlD
Progesterone—AR—female reproductive system—urinary bladder cancer	0.000414	0.00543	CbGeAlD
Progesterone—ESR1—female reproductive system—urinary bladder cancer	0.000407	0.00533	CbGeAlD
Progesterone—NR3C1—epithelium—urinary bladder cancer	0.000404	0.0053	CbGeAlD
Progesterone—CYP1A2—renal system—urinary bladder cancer	0.000391	0.00513	CbGeAlD
Progesterone—NR3C1—smooth muscle tissue—urinary bladder cancer	0.000389	0.00511	CbGeAlD
Progesterone—CYP1A1—renal system—urinary bladder cancer	0.000386	0.00507	CbGeAlD
Progesterone—CYP1A1—urethra—urinary bladder cancer	0.000379	0.00498	CbGeAlD
Progesterone—CYP3A5—renal system—urinary bladder cancer	0.000378	0.00495	CbGeAlD
Progesterone—AR—vagina—urinary bladder cancer	0.000375	0.00491	CbGeAlD
Progesterone—NR3C1—renal system—urinary bladder cancer	0.000375	0.00491	CbGeAlD
Progesterone—NR3C1—urethra—urinary bladder cancer	0.000368	0.00483	CbGeAlD
Progesterone—ESR1—vagina—urinary bladder cancer	0.000368	0.00482	CbGeAlD
Progesterone—ABCC1—vagina—urinary bladder cancer	0.000356	0.00467	CbGeAlD
Progesterone—CYP2C19—vagina—urinary bladder cancer	0.000347	0.00455	CbGeAlD
Progesterone—CYP2C8—female reproductive system—urinary bladder cancer	0.000335	0.00439	CbGeAlD
Progesterone—NR3C2—lymph node—urinary bladder cancer	0.000327	0.00429	CbGeAlD
Progesterone—CYP1A1—female reproductive system—urinary bladder cancer	0.000309	0.00406	CbGeAlD
Progesterone—PGR—lymph node—urinary bladder cancer	0.000304	0.00399	CbGeAlD
Progesterone—CYP2C8—vagina—urinary bladder cancer	0.000303	0.00397	CbGeAlD
Progesterone—NR3C1—female reproductive system—urinary bladder cancer	0.0003	0.00394	CbGeAlD
Progesterone—CYP2C9—female reproductive system—urinary bladder cancer	0.000298	0.0039	CbGeAlD
Progesterone—ABCB1—prostate gland—urinary bladder cancer	0.000294	0.00386	CbGeAlD
Progesterone—Levonorgestrel—ESR1—urinary bladder cancer	0.000289	0.0801	CrCbGaD
Progesterone—CYP3A4—renal system—urinary bladder cancer	0.000283	0.00372	CbGeAlD
Progesterone—CYP1A1—vagina—urinary bladder cancer	0.00028	0.00367	CbGeAlD
Progesterone—CYP2D6—renal system—urinary bladder cancer	0.000279	0.00366	CbGeAlD
Progesterone—SLC22A3—lymph node—urinary bladder cancer	0.000278	0.00365	CbGeAlD
Progesterone—Fluoxymesterone—ESR1—urinary bladder cancer	0.000276	0.0763	CrCbGaD
Progesterone—CYP3A5—vagina—urinary bladder cancer	0.000273	0.00359	CbGeAlD
Progesterone—NR3C1—vagina—urinary bladder cancer	0.000271	0.00356	CbGeAlD
Progesterone—SIGMAR1—lymph node—urinary bladder cancer	0.000269	0.00353	CbGeAlD
Progesterone—Danazol—ESR1—urinary bladder cancer	0.000263	0.0729	CrCbGaD
Progesterone—CYP1B1—lymph node—urinary bladder cancer	0.000256	0.00336	CbGeAlD
Progesterone—ABCB1—seminal vesicle—urinary bladder cancer	0.000249	0.00326	CbGeAlD
Progesterone—AR—lymph node—urinary bladder cancer	0.000242	0.00318	CbGeAlD
Progesterone—ESR1—lymph node—urinary bladder cancer	0.000238	0.00312	CbGeAlD
Progesterone—Medroxyprogesterone Acetate—ESR1—urinary bladder cancer	0.000236	0.0655	CrCbGaD
Progesterone—ABCC1—lymph node—urinary bladder cancer	0.00023	0.00302	CbGeAlD
Progesterone—CYP3A4—female reproductive system—urinary bladder cancer	0.000227	0.00298	CbGeAlD
Progesterone—CYP2D6—female reproductive system—urinary bladder cancer	0.000223	0.00293	CbGeAlD
Progesterone—ABCB1—epithelium—urinary bladder cancer	0.000216	0.00284	CbGeAlD
Progesterone—ABCB1—renal system—urinary bladder cancer	0.000201	0.00263	CbGeAlD
Progesterone—ABCB1—urethra—urinary bladder cancer	0.000197	0.00258	CbGeAlD
Progesterone—CYP1A1—lymph node—urinary bladder cancer	0.000181	0.00237	CbGeAlD
Progesterone—Drospirenone—PTGS2—urinary bladder cancer	0.000177	0.049	CrCbGaD
Progesterone—NR3C1—lymph node—urinary bladder cancer	0.000176	0.0023	CbGeAlD
Progesterone—ABCB1—female reproductive system—urinary bladder cancer	0.000161	0.00211	CbGeAlD
Progesterone—ABCB1—vagina—urinary bladder cancer	0.000145	0.00191	CbGeAlD
Progesterone—ABCB1—lymph node—urinary bladder cancer	9.4e-05	0.00123	CbGeAlD
Progesterone—Abdominal pain—Etoposide—urinary bladder cancer	7.56e-05	0.000528	CcSEcCtD
Progesterone—Body temperature increased—Etoposide—urinary bladder cancer	7.56e-05	0.000528	CcSEcCtD
Progesterone—Urinary tract infection—Doxorubicin—urinary bladder cancer	7.56e-05	0.000528	CcSEcCtD
Progesterone—Conjunctivitis—Doxorubicin—urinary bladder cancer	7.56e-05	0.000528	CcSEcCtD
Progesterone—Haemorrhage—Epirubicin—urinary bladder cancer	7.54e-05	0.000527	CcSEcCtD
Progesterone—Hepatitis—Epirubicin—urinary bladder cancer	7.54e-05	0.000527	CcSEcCtD
Progesterone—Eye disorder—Methotrexate—urinary bladder cancer	7.53e-05	0.000527	CcSEcCtD
Progesterone—Diarrhoea—Fluorouracil—urinary bladder cancer	7.53e-05	0.000527	CcSEcCtD
Progesterone—Tinnitus—Methotrexate—urinary bladder cancer	7.52e-05	0.000525	CcSEcCtD
Progesterone—Asthenia—Cisplatin—urinary bladder cancer	7.49e-05	0.000523	CcSEcCtD
Progesterone—Pharyngitis—Epirubicin—urinary bladder cancer	7.49e-05	0.000523	CcSEcCtD
Progesterone—Cardiac disorder—Methotrexate—urinary bladder cancer	7.48e-05	0.000523	CcSEcCtD
Progesterone—Urinary tract disorder—Epirubicin—urinary bladder cancer	7.45e-05	0.000521	CcSEcCtD
Progesterone—Oedema peripheral—Epirubicin—urinary bladder cancer	7.43e-05	0.00052	CcSEcCtD
Progesterone—Connective tissue disorder—Epirubicin—urinary bladder cancer	7.41e-05	0.000518	CcSEcCtD
Progesterone—Urethral disorder—Epirubicin—urinary bladder cancer	7.39e-05	0.000517	CcSEcCtD
Progesterone—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	7.35e-05	0.000514	CcSEcCtD
Progesterone—Angiopathy—Methotrexate—urinary bladder cancer	7.31e-05	0.000511	CcSEcCtD
Progesterone—Sinusitis—Doxorubicin—urinary bladder cancer	7.29e-05	0.00051	CcSEcCtD
Progesterone—Immune system disorder—Methotrexate—urinary bladder cancer	7.28e-05	0.000509	CcSEcCtD
Progesterone—Dizziness—Fluorouracil—urinary bladder cancer	7.28e-05	0.000509	CcSEcCtD
Progesterone—Visual impairment—Epirubicin—urinary bladder cancer	7.27e-05	0.000508	CcSEcCtD
Progesterone—Mediastinal disorder—Methotrexate—urinary bladder cancer	7.26e-05	0.000508	CcSEcCtD
Progesterone—Diarrhoea—Cisplatin—urinary bladder cancer	7.14e-05	0.000499	CcSEcCtD
Progesterone—Erythema multiforme—Epirubicin—urinary bladder cancer	7.13e-05	0.000499	CcSEcCtD
Progesterone—Alopecia—Methotrexate—urinary bladder cancer	7.12e-05	0.000498	CcSEcCtD
Progesterone—Vomiting—Gemcitabine—urinary bladder cancer	7.12e-05	0.000498	CcSEcCtD
Progesterone—Mental disorder—Methotrexate—urinary bladder cancer	7.06e-05	0.000494	CcSEcCtD
Progesterone—Rash—Gemcitabine—urinary bladder cancer	7.06e-05	0.000494	CcSEcCtD
Progesterone—Dermatitis—Gemcitabine—urinary bladder cancer	7.05e-05	0.000493	CcSEcCtD
Progesterone—Eye disorder—Epirubicin—urinary bladder cancer	7.05e-05	0.000493	CcSEcCtD
Progesterone—Hypersensitivity—Etoposide—urinary bladder cancer	7.04e-05	0.000492	CcSEcCtD
Progesterone—Tinnitus—Epirubicin—urinary bladder cancer	7.03e-05	0.000492	CcSEcCtD
Progesterone—Erythema—Methotrexate—urinary bladder cancer	7.02e-05	0.000491	CcSEcCtD
Progesterone—Malnutrition—Methotrexate—urinary bladder cancer	7.02e-05	0.000491	CcSEcCtD
Progesterone—Haemoglobin—Doxorubicin—urinary bladder cancer	7.02e-05	0.00049	CcSEcCtD
Progesterone—Headache—Gemcitabine—urinary bladder cancer	7.01e-05	0.00049	CcSEcCtD
Progesterone—Cardiac disorder—Epirubicin—urinary bladder cancer	7e-05	0.000489	CcSEcCtD
Progesterone—Vomiting—Fluorouracil—urinary bladder cancer	7e-05	0.000489	CcSEcCtD
Progesterone—Rhinitis—Doxorubicin—urinary bladder cancer	7e-05	0.000489	CcSEcCtD
Progesterone—Haemorrhage—Doxorubicin—urinary bladder cancer	6.98e-05	0.000488	CcSEcCtD
Progesterone—Hepatitis—Doxorubicin—urinary bladder cancer	6.98e-05	0.000488	CcSEcCtD
Progesterone—Rash—Fluorouracil—urinary bladder cancer	6.94e-05	0.000485	CcSEcCtD
Progesterone—Dermatitis—Fluorouracil—urinary bladder cancer	6.93e-05	0.000485	CcSEcCtD
Progesterone—Pharyngitis—Doxorubicin—urinary bladder cancer	6.93e-05	0.000484	CcSEcCtD
Progesterone—Headache—Fluorouracil—urinary bladder cancer	6.9e-05	0.000482	CcSEcCtD
Progesterone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	6.89e-05	0.000482	CcSEcCtD
Progesterone—Oedema peripheral—Doxorubicin—urinary bladder cancer	6.88e-05	0.000481	CcSEcCtD
Progesterone—Asthenia—Etoposide—urinary bladder cancer	6.86e-05	0.00048	CcSEcCtD
Progesterone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	6.86e-05	0.00048	CcSEcCtD
Progesterone—Angiopathy—Epirubicin—urinary bladder cancer	6.84e-05	0.000478	CcSEcCtD
Progesterone—Urethral disorder—Doxorubicin—urinary bladder cancer	6.84e-05	0.000478	CcSEcCtD
Progesterone—Immune system disorder—Epirubicin—urinary bladder cancer	6.81e-05	0.000476	CcSEcCtD
Progesterone—Mediastinal disorder—Epirubicin—urinary bladder cancer	6.8e-05	0.000475	CcSEcCtD
Progesterone—Back pain—Methotrexate—urinary bladder cancer	6.79e-05	0.000475	CcSEcCtD
Progesterone—Pruritus—Etoposide—urinary bladder cancer	6.76e-05	0.000473	CcSEcCtD
Progesterone—Visual impairment—Doxorubicin—urinary bladder cancer	6.73e-05	0.00047	CcSEcCtD
Progesterone—Alopecia—Epirubicin—urinary bladder cancer	6.67e-05	0.000466	CcSEcCtD
Progesterone—Nausea—Gemcitabine—urinary bladder cancer	6.65e-05	0.000465	CcSEcCtD
Progesterone—Vomiting—Cisplatin—urinary bladder cancer	6.64e-05	0.000464	CcSEcCtD
Progesterone—Vision blurred—Methotrexate—urinary bladder cancer	6.61e-05	0.000462	CcSEcCtD
Progesterone—Mental disorder—Epirubicin—urinary bladder cancer	6.61e-05	0.000462	CcSEcCtD
Progesterone—Erythema multiforme—Doxorubicin—urinary bladder cancer	6.6e-05	0.000461	CcSEcCtD
Progesterone—Rash—Cisplatin—urinary bladder cancer	6.58e-05	0.00046	CcSEcCtD
Progesterone—Dermatitis—Cisplatin—urinary bladder cancer	6.57e-05	0.00046	CcSEcCtD
Progesterone—Malnutrition—Epirubicin—urinary bladder cancer	6.57e-05	0.000459	CcSEcCtD
Progesterone—Erythema—Epirubicin—urinary bladder cancer	6.57e-05	0.000459	CcSEcCtD
Progesterone—Diarrhoea—Etoposide—urinary bladder cancer	6.54e-05	0.000457	CcSEcCtD
Progesterone—Nausea—Fluorouracil—urinary bladder cancer	6.54e-05	0.000457	CcSEcCtD
Progesterone—Eye disorder—Doxorubicin—urinary bladder cancer	6.52e-05	0.000456	CcSEcCtD
Progesterone—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.51e-05	0.000455	CcSEcCtD
Progesterone—Tinnitus—Doxorubicin—urinary bladder cancer	6.51e-05	0.000455	CcSEcCtD
Progesterone—Anaemia—Methotrexate—urinary bladder cancer	6.49e-05	0.000453	CcSEcCtD
Progesterone—Cardiac disorder—Doxorubicin—urinary bladder cancer	6.48e-05	0.000453	CcSEcCtD
Progesterone—Flatulence—Epirubicin—urinary bladder cancer	6.47e-05	0.000452	CcSEcCtD
Progesterone—Tension—Epirubicin—urinary bladder cancer	6.44e-05	0.000451	CcSEcCtD
Progesterone—Nervousness—Epirubicin—urinary bladder cancer	6.38e-05	0.000446	CcSEcCtD
Progesterone—Back pain—Epirubicin—urinary bladder cancer	6.35e-05	0.000444	CcSEcCtD
Progesterone—Angiopathy—Doxorubicin—urinary bladder cancer	6.33e-05	0.000443	CcSEcCtD
Progesterone—Malaise—Methotrexate—urinary bladder cancer	6.33e-05	0.000442	CcSEcCtD
Progesterone—Dizziness—Etoposide—urinary bladder cancer	6.32e-05	0.000442	CcSEcCtD
Progesterone—Muscle spasms—Epirubicin—urinary bladder cancer	6.31e-05	0.000441	CcSEcCtD
Progesterone—Immune system disorder—Doxorubicin—urinary bladder cancer	6.3e-05	0.000441	CcSEcCtD
Progesterone—Vertigo—Methotrexate—urinary bladder cancer	6.3e-05	0.000441	CcSEcCtD
Progesterone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	6.29e-05	0.00044	CcSEcCtD
Progesterone—Nausea—Cisplatin—urinary bladder cancer	6.2e-05	0.000433	CcSEcCtD
Progesterone—Vision blurred—Epirubicin—urinary bladder cancer	6.19e-05	0.000433	CcSEcCtD
Progesterone—Alopecia—Doxorubicin—urinary bladder cancer	6.17e-05	0.000431	CcSEcCtD
Progesterone—Cough—Methotrexate—urinary bladder cancer	6.12e-05	0.000428	CcSEcCtD
Progesterone—Mental disorder—Doxorubicin—urinary bladder cancer	6.12e-05	0.000428	CcSEcCtD
Progesterone—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.09e-05	0.000426	CcSEcCtD
Progesterone—Convulsion—Methotrexate—urinary bladder cancer	6.08e-05	0.000425	CcSEcCtD
Progesterone—Vomiting—Etoposide—urinary bladder cancer	6.08e-05	0.000425	CcSEcCtD
Progesterone—Erythema—Doxorubicin—urinary bladder cancer	6.08e-05	0.000425	CcSEcCtD
Progesterone—Malnutrition—Doxorubicin—urinary bladder cancer	6.08e-05	0.000425	CcSEcCtD
Progesterone—Anaemia—Epirubicin—urinary bladder cancer	6.07e-05	0.000424	CcSEcCtD
Progesterone—Rash—Etoposide—urinary bladder cancer	6.03e-05	0.000421	CcSEcCtD
Progesterone—Dermatitis—Etoposide—urinary bladder cancer	6.02e-05	0.000421	CcSEcCtD
Progesterone—Headache—Etoposide—urinary bladder cancer	5.99e-05	0.000419	CcSEcCtD
Progesterone—Flatulence—Doxorubicin—urinary bladder cancer	5.99e-05	0.000419	CcSEcCtD
Progesterone—Myalgia—Methotrexate—urinary bladder cancer	5.97e-05	0.000418	CcSEcCtD
Progesterone—Chest pain—Methotrexate—urinary bladder cancer	5.97e-05	0.000418	CcSEcCtD
Progesterone—Arthralgia—Methotrexate—urinary bladder cancer	5.97e-05	0.000418	CcSEcCtD
Progesterone—Tension—Doxorubicin—urinary bladder cancer	5.96e-05	0.000417	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	5.93e-05	0.000415	CcSEcCtD
Progesterone—Malaise—Epirubicin—urinary bladder cancer	5.92e-05	0.000414	CcSEcCtD
Progesterone—Discomfort—Methotrexate—urinary bladder cancer	5.9e-05	0.000413	CcSEcCtD
Progesterone—Nervousness—Doxorubicin—urinary bladder cancer	5.9e-05	0.000413	CcSEcCtD
Progesterone—Vertigo—Epirubicin—urinary bladder cancer	5.9e-05	0.000412	CcSEcCtD
Progesterone—Syncope—Epirubicin—urinary bladder cancer	5.89e-05	0.000412	CcSEcCtD
Progesterone—Back pain—Doxorubicin—urinary bladder cancer	5.88e-05	0.000411	CcSEcCtD
Progesterone—Muscle spasms—Doxorubicin—urinary bladder cancer	5.84e-05	0.000408	CcSEcCtD
Progesterone—Palpitations—Epirubicin—urinary bladder cancer	5.8e-05	0.000406	CcSEcCtD
Progesterone—Confusional state—Methotrexate—urinary bladder cancer	5.77e-05	0.000404	CcSEcCtD
Progesterone—Loss of consciousness—Epirubicin—urinary bladder cancer	5.77e-05	0.000404	CcSEcCtD
Progesterone—Cough—Epirubicin—urinary bladder cancer	5.73e-05	0.000401	CcSEcCtD
Progesterone—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.73e-05	0.0004	CcSEcCtD
Progesterone—Vision blurred—Doxorubicin—urinary bladder cancer	5.73e-05	0.0004	CcSEcCtD
Progesterone—Convulsion—Epirubicin—urinary bladder cancer	5.69e-05	0.000398	CcSEcCtD
Progesterone—Infection—Methotrexate—urinary bladder cancer	5.69e-05	0.000398	CcSEcCtD
Progesterone—Nausea—Etoposide—urinary bladder cancer	5.68e-05	0.000397	CcSEcCtD
Progesterone—Hypertension—Epirubicin—urinary bladder cancer	5.67e-05	0.000396	CcSEcCtD
Progesterone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.64e-05	0.000394	CcSEcCtD
Progesterone—Nervous system disorder—Methotrexate—urinary bladder cancer	5.62e-05	0.000393	CcSEcCtD
Progesterone—Anaemia—Doxorubicin—urinary bladder cancer	5.62e-05	0.000393	CcSEcCtD
Progesterone—Chest pain—Epirubicin—urinary bladder cancer	5.59e-05	0.000391	CcSEcCtD
Progesterone—Myalgia—Epirubicin—urinary bladder cancer	5.59e-05	0.000391	CcSEcCtD
Progesterone—Arthralgia—Epirubicin—urinary bladder cancer	5.59e-05	0.000391	CcSEcCtD
Progesterone—Anxiety—Epirubicin—urinary bladder cancer	5.57e-05	0.00039	CcSEcCtD
Progesterone—Skin disorder—Methotrexate—urinary bladder cancer	5.56e-05	0.000389	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	5.55e-05	0.000388	CcSEcCtD
Progesterone—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.54e-05	0.000387	CcSEcCtD
Progesterone—Discomfort—Epirubicin—urinary bladder cancer	5.52e-05	0.000386	CcSEcCtD
Progesterone—Malaise—Doxorubicin—urinary bladder cancer	5.48e-05	0.000383	CcSEcCtD
Progesterone—Dry mouth—Epirubicin—urinary bladder cancer	5.47e-05	0.000382	CcSEcCtD
Progesterone—Vertigo—Doxorubicin—urinary bladder cancer	5.46e-05	0.000382	CcSEcCtD
Progesterone—Anorexia—Methotrexate—urinary bladder cancer	5.46e-05	0.000382	CcSEcCtD
Progesterone—Syncope—Doxorubicin—urinary bladder cancer	5.45e-05	0.000381	CcSEcCtD
Progesterone—Confusional state—Epirubicin—urinary bladder cancer	5.4e-05	0.000378	CcSEcCtD
Progesterone—Palpitations—Doxorubicin—urinary bladder cancer	5.37e-05	0.000375	CcSEcCtD
Progesterone—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.36e-05	0.000375	CcSEcCtD
Progesterone—Oedema—Epirubicin—urinary bladder cancer	5.36e-05	0.000375	CcSEcCtD
Progesterone—Hypotension—Methotrexate—urinary bladder cancer	5.35e-05	0.000374	CcSEcCtD
Progesterone—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.34e-05	0.000373	CcSEcCtD
Progesterone—Infection—Epirubicin—urinary bladder cancer	5.32e-05	0.000372	CcSEcCtD
Progesterone—Cough—Doxorubicin—urinary bladder cancer	5.3e-05	0.000371	CcSEcCtD
Progesterone—Shock—Epirubicin—urinary bladder cancer	5.27e-05	0.000369	CcSEcCtD
Progesterone—Convulsion—Doxorubicin—urinary bladder cancer	5.26e-05	0.000368	CcSEcCtD
Progesterone—Nervous system disorder—Epirubicin—urinary bladder cancer	5.26e-05	0.000367	CcSEcCtD
Progesterone—Hypertension—Doxorubicin—urinary bladder cancer	5.25e-05	0.000367	CcSEcCtD
Progesterone—Tachycardia—Epirubicin—urinary bladder cancer	5.23e-05	0.000366	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.22e-05	0.000365	CcSEcCtD
Progesterone—Skin disorder—Epirubicin—urinary bladder cancer	5.21e-05	0.000364	CcSEcCtD
Progesterone—Hyperhidrosis—Epirubicin—urinary bladder cancer	5.18e-05	0.000362	CcSEcCtD
Progesterone—Insomnia—Methotrexate—urinary bladder cancer	5.18e-05	0.000362	CcSEcCtD
Progesterone—Myalgia—Doxorubicin—urinary bladder cancer	5.17e-05	0.000362	CcSEcCtD
Progesterone—Chest pain—Doxorubicin—urinary bladder cancer	5.17e-05	0.000362	CcSEcCtD
Progesterone—Arthralgia—Doxorubicin—urinary bladder cancer	5.17e-05	0.000362	CcSEcCtD
Progesterone—Anxiety—Doxorubicin—urinary bladder cancer	5.16e-05	0.00036	CcSEcCtD
Progesterone—Paraesthesia—Methotrexate—urinary bladder cancer	5.14e-05	0.00036	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.14e-05	0.000359	CcSEcCtD
Progesterone—Discomfort—Doxorubicin—urinary bladder cancer	5.11e-05	0.000357	CcSEcCtD
Progesterone—Anorexia—Epirubicin—urinary bladder cancer	5.11e-05	0.000357	CcSEcCtD
Progesterone—Dyspnoea—Methotrexate—urinary bladder cancer	5.11e-05	0.000357	CcSEcCtD
Progesterone—Somnolence—Methotrexate—urinary bladder cancer	5.09e-05	0.000356	CcSEcCtD
Progesterone—Dry mouth—Doxorubicin—urinary bladder cancer	5.06e-05	0.000354	CcSEcCtD
Progesterone—Dyspepsia—Methotrexate—urinary bladder cancer	5.04e-05	0.000352	CcSEcCtD
Progesterone—Hypotension—Epirubicin—urinary bladder cancer	5.01e-05	0.00035	CcSEcCtD
Progesterone—Confusional state—Doxorubicin—urinary bladder cancer	5e-05	0.00035	CcSEcCtD
Progesterone—Decreased appetite—Methotrexate—urinary bladder cancer	4.98e-05	0.000348	CcSEcCtD
Progesterone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	4.96e-05	0.000347	CcSEcCtD
Progesterone—Oedema—Doxorubicin—urinary bladder cancer	4.96e-05	0.000347	CcSEcCtD
Progesterone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	4.94e-05	0.000346	CcSEcCtD
Progesterone—Fatigue—Methotrexate—urinary bladder cancer	4.94e-05	0.000345	CcSEcCtD
Progesterone—Infection—Doxorubicin—urinary bladder cancer	4.93e-05	0.000344	CcSEcCtD
Progesterone—Pain—Methotrexate—urinary bladder cancer	4.9e-05	0.000342	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.88e-05	0.000341	CcSEcCtD
Progesterone—Shock—Doxorubicin—urinary bladder cancer	4.88e-05	0.000341	CcSEcCtD
Progesterone—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.86e-05	0.00034	CcSEcCtD
Progesterone—Insomnia—Epirubicin—urinary bladder cancer	4.85e-05	0.000339	CcSEcCtD
Progesterone—Tachycardia—Doxorubicin—urinary bladder cancer	4.84e-05	0.000338	CcSEcCtD
Progesterone—Skin disorder—Doxorubicin—urinary bladder cancer	4.82e-05	0.000337	CcSEcCtD
Progesterone—Paraesthesia—Epirubicin—urinary bladder cancer	4.81e-05	0.000336	CcSEcCtD
Progesterone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.79e-05	0.000335	CcSEcCtD
Progesterone—Dyspnoea—Epirubicin—urinary bladder cancer	4.78e-05	0.000334	CcSEcCtD
Progesterone—Somnolence—Epirubicin—urinary bladder cancer	4.76e-05	0.000333	CcSEcCtD
Progesterone—Anorexia—Doxorubicin—urinary bladder cancer	4.73e-05	0.00033	CcSEcCtD
Progesterone—Feeling abnormal—Methotrexate—urinary bladder cancer	4.72e-05	0.00033	CcSEcCtD
Progesterone—Dyspepsia—Epirubicin—urinary bladder cancer	4.72e-05	0.00033	CcSEcCtD
Progesterone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.68e-05	0.000327	CcSEcCtD
Progesterone—Decreased appetite—Epirubicin—urinary bladder cancer	4.66e-05	0.000326	CcSEcCtD
Progesterone—Hypotension—Doxorubicin—urinary bladder cancer	4.63e-05	0.000324	CcSEcCtD
Progesterone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.63e-05	0.000323	CcSEcCtD
Progesterone—Fatigue—Epirubicin—urinary bladder cancer	4.62e-05	0.000323	CcSEcCtD
Progesterone—Constipation—Epirubicin—urinary bladder cancer	4.58e-05	0.00032	CcSEcCtD
Progesterone—Pain—Epirubicin—urinary bladder cancer	4.58e-05	0.00032	CcSEcCtD
Progesterone—Urticaria—Methotrexate—urinary bladder cancer	4.55e-05	0.000318	CcSEcCtD
Progesterone—Abdominal pain—Methotrexate—urinary bladder cancer	4.53e-05	0.000317	CcSEcCtD
Progesterone—Body temperature increased—Methotrexate—urinary bladder cancer	4.53e-05	0.000317	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.52e-05	0.000316	CcSEcCtD
Progesterone—Insomnia—Doxorubicin—urinary bladder cancer	4.49e-05	0.000314	CcSEcCtD
Progesterone—Paraesthesia—Doxorubicin—urinary bladder cancer	4.45e-05	0.000311	CcSEcCtD
Progesterone—Dyspnoea—Doxorubicin—urinary bladder cancer	4.42e-05	0.000309	CcSEcCtD
Progesterone—Feeling abnormal—Epirubicin—urinary bladder cancer	4.42e-05	0.000309	CcSEcCtD
Progesterone—Somnolence—Doxorubicin—urinary bladder cancer	4.41e-05	0.000308	CcSEcCtD
Progesterone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.38e-05	0.000306	CcSEcCtD
Progesterone—Dyspepsia—Doxorubicin—urinary bladder cancer	4.37e-05	0.000305	CcSEcCtD
Progesterone—Decreased appetite—Doxorubicin—urinary bladder cancer	4.31e-05	0.000301	CcSEcCtD
Progesterone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.28e-05	0.000299	CcSEcCtD
Progesterone—Fatigue—Doxorubicin—urinary bladder cancer	4.28e-05	0.000299	CcSEcCtD
Progesterone—Urticaria—Epirubicin—urinary bladder cancer	4.26e-05	0.000298	CcSEcCtD
Progesterone—Constipation—Doxorubicin—urinary bladder cancer	4.24e-05	0.000296	CcSEcCtD
Progesterone—Pain—Doxorubicin—urinary bladder cancer	4.24e-05	0.000296	CcSEcCtD
Progesterone—Body temperature increased—Epirubicin—urinary bladder cancer	4.24e-05	0.000296	CcSEcCtD
Progesterone—Abdominal pain—Epirubicin—urinary bladder cancer	4.24e-05	0.000296	CcSEcCtD
Progesterone—Hypersensitivity—Methotrexate—urinary bladder cancer	4.22e-05	0.000295	CcSEcCtD
Progesterone—Asthenia—Methotrexate—urinary bladder cancer	4.11e-05	0.000287	CcSEcCtD
Progesterone—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.09e-05	0.000286	CcSEcCtD
Progesterone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.06e-05	0.000283	CcSEcCtD
Progesterone—Pruritus—Methotrexate—urinary bladder cancer	4.05e-05	0.000283	CcSEcCtD
Progesterone—Hypersensitivity—Epirubicin—urinary bladder cancer	3.95e-05	0.000276	CcSEcCtD
Progesterone—Urticaria—Doxorubicin—urinary bladder cancer	3.94e-05	0.000275	CcSEcCtD
Progesterone—Body temperature increased—Doxorubicin—urinary bladder cancer	3.92e-05	0.000274	CcSEcCtD
Progesterone—Abdominal pain—Doxorubicin—urinary bladder cancer	3.92e-05	0.000274	CcSEcCtD
Progesterone—Diarrhoea—Methotrexate—urinary bladder cancer	3.92e-05	0.000274	CcSEcCtD
Progesterone—Asthenia—Epirubicin—urinary bladder cancer	3.85e-05	0.000269	CcSEcCtD
Progesterone—Pruritus—Epirubicin—urinary bladder cancer	3.79e-05	0.000265	CcSEcCtD
Progesterone—Dizziness—Methotrexate—urinary bladder cancer	3.79e-05	0.000265	CcSEcCtD
Progesterone—Diarrhoea—Epirubicin—urinary bladder cancer	3.67e-05	0.000256	CcSEcCtD
Progesterone—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.65e-05	0.000255	CcSEcCtD
Progesterone—Vomiting—Methotrexate—urinary bladder cancer	3.64e-05	0.000255	CcSEcCtD
Progesterone—Rash—Methotrexate—urinary bladder cancer	3.61e-05	0.000252	CcSEcCtD
Progesterone—Dermatitis—Methotrexate—urinary bladder cancer	3.61e-05	0.000252	CcSEcCtD
Progesterone—Headache—Methotrexate—urinary bladder cancer	3.59e-05	0.000251	CcSEcCtD
Progesterone—Asthenia—Doxorubicin—urinary bladder cancer	3.56e-05	0.000249	CcSEcCtD
Progesterone—Dizziness—Epirubicin—urinary bladder cancer	3.54e-05	0.000248	CcSEcCtD
Progesterone—Pruritus—Doxorubicin—urinary bladder cancer	3.51e-05	0.000245	CcSEcCtD
Progesterone—Vomiting—Epirubicin—urinary bladder cancer	3.41e-05	0.000238	CcSEcCtD
Progesterone—Nausea—Methotrexate—urinary bladder cancer	3.4e-05	0.000238	CcSEcCtD
Progesterone—Diarrhoea—Doxorubicin—urinary bladder cancer	3.39e-05	0.000237	CcSEcCtD
Progesterone—Rash—Epirubicin—urinary bladder cancer	3.38e-05	0.000236	CcSEcCtD
Progesterone—Dermatitis—Epirubicin—urinary bladder cancer	3.38e-05	0.000236	CcSEcCtD
Progesterone—Headache—Epirubicin—urinary bladder cancer	3.36e-05	0.000235	CcSEcCtD
Progesterone—Dizziness—Doxorubicin—urinary bladder cancer	3.28e-05	0.000229	CcSEcCtD
Progesterone—Nausea—Epirubicin—urinary bladder cancer	3.18e-05	0.000223	CcSEcCtD
Progesterone—Vomiting—Doxorubicin—urinary bladder cancer	3.15e-05	0.00022	CcSEcCtD
Progesterone—Rash—Doxorubicin—urinary bladder cancer	3.13e-05	0.000219	CcSEcCtD
Progesterone—Dermatitis—Doxorubicin—urinary bladder cancer	3.12e-05	0.000218	CcSEcCtD
Progesterone—Headache—Doxorubicin—urinary bladder cancer	3.11e-05	0.000217	CcSEcCtD
Progesterone—Nausea—Doxorubicin—urinary bladder cancer	2.95e-05	0.000206	CcSEcCtD
Progesterone—CYP2D6—Metabolism—ENO2—urinary bladder cancer	6.38e-06	5.88e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	6.33e-06	5.83e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—ENO2—urinary bladder cancer	6.33e-06	5.83e-05	CbGpPWpGaD
Progesterone—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	6.31e-06	5.81e-05	CbGpPWpGaD
Progesterone—ABCC1—Metabolism—PPARG—urinary bladder cancer	6.3e-06	5.81e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.29e-06	5.8e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—NQO1—urinary bladder cancer	6.27e-06	5.77e-05	CbGpPWpGaD
Progesterone—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	6.22e-06	5.73e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	6.19e-06	5.7e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	6.16e-06	5.68e-05	CbGpPWpGaD
Progesterone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.15e-06	5.67e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	6.14e-06	5.65e-05	CbGpPWpGaD
Progesterone—CYP1B1—Metabolism—PPARG—urinary bladder cancer	6.1e-06	5.62e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.08e-06	5.6e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—CREBBP—urinary bladder cancer	6.08e-06	5.6e-05	CbGpPWpGaD
Progesterone—ABCC1—Metabolism—CREBBP—urinary bladder cancer	6.06e-06	5.58e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—ERBB2—urinary bladder cancer	6.06e-06	5.58e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.04e-06	5.57e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	6.04e-06	5.56e-05	CbGpPWpGaD
Progesterone—SLC22A3—Metabolism—PTEN—urinary bladder cancer	6.01e-06	5.53e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—IGF1—urinary bladder cancer	6e-06	5.53e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling by GPCR—EGFR—urinary bladder cancer	5.97e-06	5.5e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—PTGS2—urinary bladder cancer	5.92e-06	5.46e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—IL2—urinary bladder cancer	5.89e-06	5.42e-05	CbGpPWpGaD
Progesterone—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	5.86e-06	5.4e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—RRM2—urinary bladder cancer	5.84e-06	5.38e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—TERT—urinary bladder cancer	5.83e-06	5.37e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.78e-06	5.33e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	5.77e-06	5.32e-05	CbGpPWpGaD
Progesterone—ABCB11—Metabolism—PTEN—urinary bladder cancer	5.76e-06	5.3e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—CCND1—urinary bladder cancer	5.74e-06	5.29e-05	CbGpPWpGaD
Progesterone—SLC22A3—Metabolism—EP300—urinary bladder cancer	5.73e-06	5.28e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	5.7e-06	5.25e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling by GPCR—KRAS—urinary bladder cancer	5.64e-06	5.2e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—TYMS—urinary bladder cancer	5.61e-06	5.17e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—NQO1—urinary bladder cancer	5.59e-06	5.15e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—MMP9—urinary bladder cancer	5.57e-06	5.13e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	5.55e-06	5.12e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	5.55e-06	5.11e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	5.55e-06	5.11e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—PTEN—urinary bladder cancer	5.54e-06	5.1e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.52e-06	5.08e-05	CbGpPWpGaD
Progesterone—CYP3A7—Metabolism—PPARG—urinary bladder cancer	5.5e-06	5.07e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—RHOA—urinary bladder cancer	5.5e-06	5.06e-05	CbGpPWpGaD
Progesterone—ABCB11—Metabolism—EP300—urinary bladder cancer	5.49e-06	5.06e-05	CbGpPWpGaD
Progesterone—SLC22A2—Metabolism—PPARG—urinary bladder cancer	5.49e-06	5.06e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—NQO1—urinary bladder cancer	5.46e-06	5.03e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.43e-06	5e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—ENO2—urinary bladder cancer	5.41e-06	4.98e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	5.41e-06	4.98e-05	CbGpPWpGaD
Progesterone—AR—Gene Expression—MYC—urinary bladder cancer	5.4e-06	4.97e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.38e-06	4.95e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—FGFR3—urinary bladder cancer	5.35e-06	4.93e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—GPX1—urinary bladder cancer	5.31e-06	4.89e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.3e-06	4.89e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—TYMS—urinary bladder cancer	5.3e-06	4.88e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—EP300—urinary bladder cancer	5.28e-06	4.87e-05	CbGpPWpGaD
Progesterone—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	5.28e-06	4.87e-05	CbGpPWpGaD
Progesterone—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	5.27e-06	4.86e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	5.25e-06	4.83e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	5.24e-06	4.83e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	5.24e-06	4.83e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	5.23e-06	4.82e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.22e-06	4.81e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	5.21e-06	4.8e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—CDKN1A—urinary bladder cancer	5.18e-06	4.77e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.16e-06	4.76e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—PTEN—urinary bladder cancer	5.16e-06	4.76e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	5.15e-06	4.74e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—SRC—urinary bladder cancer	5.14e-06	4.73e-05	CbGpPWpGaD
Progesterone—SLC22A1—Metabolism—PPARG—urinary bladder cancer	5.12e-06	4.71e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—NQO1—urinary bladder cancer	5.1e-06	4.7e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—ERBB2—urinary bladder cancer	5.09e-06	4.69e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.06e-06	4.66e-05	CbGpPWpGaD
Progesterone—CYP2A6—Metabolism—PPARG—urinary bladder cancer	5.04e-06	4.64e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—GPX1—urinary bladder cancer	5.02e-06	4.62e-05	CbGpPWpGaD
Progesterone—ABCC1—Metabolism—PTGS2—urinary bladder cancer	4.96e-06	4.57e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.95e-06	4.56e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	4.93e-06	4.54e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—EP300—urinary bladder cancer	4.93e-06	4.54e-05	CbGpPWpGaD
Progesterone—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	4.92e-06	4.53e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	4.9e-06	4.52e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—TYMS—urinary bladder cancer	4.86e-06	4.48e-05	CbGpPWpGaD
Progesterone—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	4.84e-06	4.46e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—CXCL8—urinary bladder cancer	4.83e-06	4.45e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	4.8e-06	4.43e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	4.8e-06	4.43e-05	CbGpPWpGaD
Progesterone—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	4.8e-06	4.42e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling by GPCR—HRAS—urinary bladder cancer	4.79e-06	4.42e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—SRC—urinary bladder cancer	4.79e-06	4.41e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.73e-06	4.36e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	4.67e-06	4.3e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	4.63e-06	4.27e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—IL2—urinary bladder cancer	4.61e-06	4.25e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—MYC—urinary bladder cancer	4.6e-06	4.24e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—GPX1—urinary bladder cancer	4.6e-06	4.24e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	4.55e-06	4.2e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—CREBBP—urinary bladder cancer	4.55e-06	4.19e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	4.52e-06	4.16e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.51e-06	4.16e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.51e-06	4.15e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—EGFR—urinary bladder cancer	4.5e-06	4.15e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—IGF1—urinary bladder cancer	4.5e-06	4.14e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—CCND1—urinary bladder cancer	4.5e-06	4.14e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	4.36e-06	4.02e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—NQO1—urinary bladder cancer	4.36e-06	4.02e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.35e-06	4.01e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	4.34e-06	4e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—TYMS—urinary bladder cancer	4.34e-06	4e-05	CbGpPWpGaD
Progesterone—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	4.33e-06	3.98e-05	CbGpPWpGaD
Progesterone—ABCC1—Metabolism—PTEN—urinary bladder cancer	4.33e-06	3.98e-05	CbGpPWpGaD
Progesterone—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	4.32e-06	3.98e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.32e-06	3.98e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—MYC—urinary bladder cancer	4.29e-06	3.95e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.29e-06	3.95e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	4.29e-06	3.95e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	4.29e-06	3.95e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—KRAS—urinary bladder cancer	4.25e-06	3.92e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	4.25e-06	3.92e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	4.25e-06	3.91e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.23e-06	3.9e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.23e-06	3.9e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—EGFR—urinary bladder cancer	4.2e-06	3.87e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.19e-06	3.86e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.19e-06	3.86e-05	CbGpPWpGaD
Progesterone—CYP1B1—Metabolism—PTEN—urinary bladder cancer	4.18e-06	3.85e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.17e-06	3.84e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.17e-06	3.84e-05	CbGpPWpGaD
Progesterone—ESR1—Gene Expression—MYC—urinary bladder cancer	4.16e-06	3.83e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	4.14e-06	3.81e-05	CbGpPWpGaD
Progesterone—ABCC1—Metabolism—EP300—urinary bladder cancer	4.12e-06	3.8e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—RHOA—urinary bladder cancer	4.12e-06	3.79e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.12e-06	3.79e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—GPX1—urinary bladder cancer	4.11e-06	3.78e-05	CbGpPWpGaD
Progesterone—NR3C1—Gene Expression—MYC—urinary bladder cancer	4.09e-06	3.77e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.05e-06	3.73e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	4.03e-06	3.71e-05	CbGpPWpGaD
Progesterone—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	4.03e-06	3.71e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	4.02e-06	3.71e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.01e-06	3.69e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.99e-06	3.68e-05	CbGpPWpGaD
Progesterone—CYP1B1—Metabolism—EP300—urinary bladder cancer	3.99e-06	3.67e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—PPARG—urinary bladder cancer	3.97e-06	3.66e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—KRAS—urinary bladder cancer	3.97e-06	3.65e-05	CbGpPWpGaD
Progesterone—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	3.96e-06	3.65e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.96e-06	3.64e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.94e-06	3.63e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.94e-06	3.63e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	3.93e-06	3.62e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.91e-06	3.6e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.91e-06	3.6e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	3.82e-06	3.52e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—ERBB2—urinary bladder cancer	3.81e-06	3.51e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	3.79e-06	3.49e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—TP53—urinary bladder cancer	3.78e-06	3.48e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.78e-06	3.48e-05	CbGpPWpGaD
Progesterone—CYP3A7—Metabolism—PTEN—urinary bladder cancer	3.77e-06	3.47e-05	CbGpPWpGaD
Progesterone—SLC22A2—Metabolism—PTEN—urinary bladder cancer	3.77e-06	3.47e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—PPARG—urinary bladder cancer	3.76e-06	3.46e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.74e-06	3.45e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.71e-06	3.42e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.7e-06	3.41e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.69e-06	3.4e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.68e-06	3.39e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	3.64e-06	3.35e-05	CbGpPWpGaD
Progesterone—PGR—Signaling Pathways—HRAS—urinary bladder cancer	3.62e-06	3.33e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—CXCL8—urinary bladder cancer	3.62e-06	3.33e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	3.61e-06	3.32e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	3.61e-06	3.32e-05	CbGpPWpGaD
Progesterone—CYP3A7—Metabolism—EP300—urinary bladder cancer	3.6e-06	3.31e-05	CbGpPWpGaD
Progesterone—SLC22A2—Metabolism—EP300—urinary bladder cancer	3.59e-06	3.31e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	3.53e-06	3.25e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.52e-06	3.24e-05	CbGpPWpGaD
Progesterone—SLC22A1—Metabolism—PTEN—urinary bladder cancer	3.51e-06	3.23e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.49e-06	3.21e-05	CbGpPWpGaD
Progesterone—CYP2A6—Metabolism—PTEN—urinary bladder cancer	3.46e-06	3.19e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—IL2—urinary bladder cancer	3.46e-06	3.18e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.46e-06	3.18e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—PPARG—urinary bladder cancer	3.44e-06	3.17e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.38e-06	3.11e-05	CbGpPWpGaD
Progesterone—ABCC1—Disease—HRAS—urinary bladder cancer	3.37e-06	3.11e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—CCND1—urinary bladder cancer	3.37e-06	3.1e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.36e-06	3.1e-05	CbGpPWpGaD
Progesterone—SLC22A1—Metabolism—EP300—urinary bladder cancer	3.35e-06	3.08e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.34e-06	3.08e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.34e-06	3.08e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	3.33e-06	3.07e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	3.31e-06	3.05e-05	CbGpPWpGaD
Progesterone—CYP2A6—Metabolism—EP300—urinary bladder cancer	3.3e-06	3.04e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—MMP9—urinary bladder cancer	3.27e-06	3.01e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—CDKN1A—urinary bladder cancer	3.26e-06	3e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—PTEN—urinary bladder cancer	3.25e-06	3e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.2e-06	2.95e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.14e-06	2.89e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	3.13e-06	2.88e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—EP300—urinary bladder cancer	3.1e-06	2.86e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—PPARG—urinary bladder cancer	3.07e-06	2.83e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—SRC—urinary bladder cancer	3.02e-06	2.78e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—PPARG—urinary bladder cancer	3e-06	2.76e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	2.96e-06	2.73e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	2.95e-06	2.72e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.95e-06	2.72e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.95e-06	2.72e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.88e-06	2.65e-05	CbGpPWpGaD
Progesterone—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	2.83e-06	2.61e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.83e-06	2.6e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.81e-06	2.58e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.8e-06	2.58e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	2.73e-06	2.51e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.72e-06	2.5e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	2.71e-06	2.49e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—MYC—urinary bladder cancer	2.7e-06	2.49e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.69e-06	2.48e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—EGFR—urinary bladder cancer	2.64e-06	2.43e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.61e-06	2.4e-05	CbGpPWpGaD
Progesterone—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.6e-06	2.4e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.58e-06	2.38e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.58e-06	2.38e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—PTEN—urinary bladder cancer	2.58e-06	2.37e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—KRAS—urinary bladder cancer	2.5e-06	2.3e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.47e-06	2.27e-05	CbGpPWpGaD
Progesterone—CYP1A1—Metabolism—EP300—urinary bladder cancer	2.46e-06	2.26e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.42e-06	2.23e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.42e-06	2.23e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.39e-06	2.21e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—PTEN—urinary bladder cancer	2.36e-06	2.18e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.36e-06	2.17e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.3e-06	2.12e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.28e-06	2.1e-05	CbGpPWpGaD
Progesterone—CYP2C8—Metabolism—EP300—urinary bladder cancer	2.25e-06	2.07e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.22e-06	2.05e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—TP53—urinary bladder cancer	2.22e-06	2.04e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.2e-06	2.03e-05	CbGpPWpGaD
Progesterone—ESR1—Signaling Pathways—HRAS—urinary bladder cancer	2.12e-06	1.96e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—PTEN—urinary bladder cancer	2.11e-06	1.94e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.06e-06	1.9e-05	CbGpPWpGaD
Progesterone—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.01e-06	1.85e-05	CbGpPWpGaD
Progesterone—ABCB1—Metabolism—EP300—urinary bladder cancer	1.96e-06	1.81e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.94e-06	1.79e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.92e-06	1.77e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.88e-06	1.74e-05	CbGpPWpGaD
Progesterone—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.85e-06	1.7e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.85e-06	1.7e-05	CbGpPWpGaD
Progesterone—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.83e-06	1.69e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.78e-06	1.64e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.64e-06	1.51e-05	CbGpPWpGaD
Progesterone—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.57e-06	1.44e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.45e-06	1.34e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Progesterone—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.21e-06	1.11e-05	CbGpPWpGaD
